Venlafaxine: Nursing Drug Guide, Discontinuation Syndrome & Hold Rules
Venlafaxine is an SNRI for adult depression and anxiety disorders. The bedside safety story is never stop or miss doses without a taper plan—postmarketing reports describe protracted discontinuation symptoms including electric-shock sensations, aggression, and suicidal thoughts during dose reduction—plus serotonin syndrome when serotonergic drugs stack and sustained blood pressure elevation during therapy.
Gradually reduce venlafaxine whenever possible—abrupt stop or rapid taper can cause protracted, severe discontinuation symptoms; postmarketing reports include completed suicide, suicidal thoughts, and severe aggression during dose reduction. MAOIs (including linezolid or IV methylene blue within required washout windows) are contraindicated. Stacking with other serotonergic agents increases serotonin syndrome risk. Control pre-existing hypertension before starting and monitor blood pressure regularly. Extended-release capsules must be swallowed whole—do not divide, crush, or chew unless pharmacy directs the approved sprinkle technique.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: confirm formulation (XR vs IR), verify MAOI/serotonergic washouts, trend blood pressure, and treat missed doses as a discontinuation risk—not a silent omission. Hold and clarify when serotonin syndrome is suspected, multiple doses were missed without a restart plan, sustained hypertension appears, or the patient cannot swallow the capsule whole without an approved alternate method.
Most common brand names
Venlafaxine is available as generic extended-release capsules/tablets and as brands including Effexor XR (extended-release) and immediate-release Effexor. Verify both drug name, formulation (XR vs IR), and capsule strength—look-alike confusion with desvenlafaxine and other antidepressants is a common source of inpatient errors.
Effexor XR capsules contain venlafaxine hydrochloride equivalent to 37.5 mg, 75 mg, or 150 mg venlafaxine. Desvenlafaxine is the major active metabolite of venlafaxine but is a distinct product—do not substitute milligram-for-milligram.
Why we give it — Indications
Effexor XR is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated in adults for:
| Use | Detail |
|---|---|
| Major depressive disorder (MDD) | Typical starting dose 75 mg once daily (may begin 37.5 mg daily for 4–7 days); may titrate to maximum 225 mg/day in increments of up to 75 mg at intervals of not less than 4 days for non-responders per labeling. |
| Generalized anxiety, social anxiety, and panic disorder | Anxiety disorders and panic disorder use indication-specific starting doses (often 37.5–75 mg/day) with labeled maximums—verify the order matches the diagnosis. Not approved for pediatric patients. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
The antidepressant/anxiolytic mechanism is unclear but is thought to involve potentiation of serotonin and norepinephrine in the central nervous system through reuptake inhibition. Venlafaxine is metabolized to O-desmethylvenlafaxine (ODV), also active. Effexor XR provides once-daily extended release; altering the capsule (crushing or chewing) can change drug exposure unless the approved sprinkle method is used.
Dosing overview
Dosing varies by indication and formulation. Effexor XR is taken once daily with food at about the same time. Increase at labeled intervals (typically ≥4 days for MDD/GAD/SAD; ≥7 days for panic disorder). When discontinuing, reduce gradually—in clinical studies tapering reduced the daily dose by 75 mg at one-week intervals, though individualization may require months.
Missed dose: Not specified in the reviewed prescribing information for a single missed dose. Nursing practice: do not double doses; notify prescriber/pharmacist after consecutive missed extended-release doses because discontinuation symptoms may emerge—document per protocol.
Before you give it — Safety check
Quick safety priorities
| Risk | Why it matters | Nursing action |
|---|---|---|
| Discontinuation / missed doses | Abrupt stop or omission can cause electric-shock sensations, agitation, insomnia, and suicidal thoughts per labeling | Never restart full dose after gaps without prescriber plan; coordinate taper |
| Serotonin syndrome | Risk with MAOIs, linezolid, and serotonergic co-therapy—even venlafaxine alone per labeling | Reconcile MAR each shift; hold and escalate for agitation, clonus, hyperthermia |
| Blood pressure elevation | Dose-related sustained hypertension may require dose reduction or stop | Baseline and serial BP; notify prescriber for sustained rise |
| Bleeding with NSAIDs, aspirin, antiplatelets, or anticoagulants | Labeling warns increased bleeding risk when combined with NSAIDs, aspirin, warfarin, or other anticoagulants | Reconcile OTC NSAIDs; monitor bruising/GI bleed and INR when warfarin co-prescribed; teach melena or hematemesis reporting |
On a small screen, swipe or scroll sideways to see the full table.
Pretreatment checks
- Confirm indication, allergies (including desvenlafaxine/venlafaxine hypersensitivity), and MAOI/linezolid/IV methylene blue status with required washout intervals (14 days after MAOI before start; 7 days after stop before MAOI)
- Blood pressure and cardiovascular history; control hypertension before initiation; review renal/hepatic function for dose limits
- Screen for suicidal ideation, bipolar history, serotonergic home medications (tramadol, triptans, other SNRIs/SSRIs)
Contraindications
- Hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate, or formulation excipients (angioedema/anaphylaxis reported)
- Concomitant MAOIs intended to treat psychiatric disorders, or within 14 days of stopping an MAOI; do not start venlafaxine within 14 days of stopping an MAOI
- Starting venlafaxine in a patient treated with linezolid or intravenous methylene blue (serotonin syndrome risk)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| MAOIs / linezolid / IV methylene blue | Contraindicated — serotonin syndrome risk | Hold venlafaxine; ensure 14-day washout before SNRI after MAOI; 7-day washout after stopping venlafaxine before MAOI |
| Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, lithium, St. John’s wort) | Increased serotonin syndrome risk—even venlafaxine alone can precipitate syndrome per labeling | Reconcile each shift; hold and escalate for agitation, hyperreflexia, autonomic instability, hyperthermia |
| NSAIDs / antiplatelets / anticoagulants | Increased bleeding risk (e.g., ibuprofen, aspirin, warfarin) | Monitor bruising, GI bleeding, INR trends when warfarin co-prescribed; patient teaching on reporting bleeding |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral extended-release capsule once daily with food (morning or evening at about the same time). Swallow whole with fluid.
- Do not divide, crush, chew, or dissolve capsules unless pharmacy implements the labeling-approved sprinkle-on-applesauce method (swallow immediately without chewing, follow with water)
- Verify XR vs immediate-release product and strength (37.5, 75, 150 mg) before every dose
- When tapering or discontinuing, follow prescriber taper—example labeling taper reduces dose by 75 mg weekly; some patients require months
Abrupt discontinuation or missed doses can precipitate discontinuation syndrome including sensory disturbances (electric-shock sensations), agitation, insomnia, dizziness, and suicidal thoughts. If intolerable symptoms follow a dose decrease, prescriber may resume prior dose then taper more slowly.
Expected therapeutic response
- Gradual improvement in depressive or anxiety symptoms over weeks—not immediate relief
- Early GI or activation effects (nausea, insomnia) may appear before mood benefit—monitor adherence and suicidality
- Blood pressure should remain controlled; sustained increases may require dose reduction per prescriber
Red flags — Stop and act
Stop the drug (with prescriber notification), monitor closely, and escalate when life-threatening toxicity or discontinuation crisis is suspected.
- Serotonin syndrome: agitation, hallucinations, tachycardia, labile BP, hyperthermia, tremor, rigidity, clonus, diarrhea
- Discontinuation syndrome after missed doses or self-reduction: electric-shock sensations, severe dizziness, irritability, aggression, suicidal thoughts
- Sustained blood pressure elevation or hypertensive symptoms requiring immediate treatment per labeling
- Seizure, syncope, or altered mental status (including suspected overdose)
- Severe hyponatremia signs: confusion, weakness, unsteadiness, seizures—serum sodium <110 mmol/L reported in labeling
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Nausea, dry mouth, constipation | Common in MDD/GAD/SAD/PD trials (e.g., nausea 30.0%, dry mouth 14.8%, constipation 9.3% at ≥5% and ≥2× placebo) | Give with food if tolerated; supportive care; document persistent vomiting or dehydration |
| Dizziness, somnolence, insomnia | Common (somnolence 15.3%; insomnia in discontinuation syndrome) | Fall precautions; orthostatic vitals in older adults; screen mood if activation worsens |
| Hyperhidrosis, anorexia | Common (sweating 11.4%, anorexia 9.8% at ≥5% and ≥2× placebo) | Monitor hydration and weight; assess tolerability and adherence |
| Elevated blood pressure | Dose-related; sustained hypertension reported—may require dose reduction or discontinuation | Baseline and serial BP; hold and notify if hypertensive emergency or sustained rise per prescriber limits |
| Serotonin syndrome | Potentially life-threatening; risk with serotonergic co-medications, MAOIs, or venlafaxine alone per labeling | Stop venlafaxine and serotonergic agents; supportive care; urgent escalation |
| Discontinuation syndrome | Protracted/severe symptoms reported postmarketing—including suicidal thoughts and aggression during dose reduction | Do not restart full dose after missed doses without prescriber plan; coordinate gradual taper |
| Hyponatremia / SIADH | Serious; serum sodium <110 mmol/L reported; elderly and diuretic users at greater risk | Check sodium if confusion, headache, falls; hold and treat per protocol |
| Bleeding | Increased risk with aspirin, NSAIDs, warfarin per labeling | Monitor bruising and GI bleeding; educate on reporting melena or hematemesis |
| Sexual dysfunction | Common in males (abnormal ejaculation 9.9%, impotence 5.3%; decreased libido 5.1% at ≥5% and ≥2× placebo) | Nonjudgmental assessment; coordinate with prescriber if adherence affected |
On a small screen, swipe or scroll sideways to see the full table.
Frequency data above reflect Effexor XR placebo-controlled trial labeling unless noted as postmarketing.
Overdose, toxicity, and antidote
Postmarketing overdose with venlafaxine has occurred predominantly with alcohol and/or other drugs. Reported events include tachycardia, altered consciousness (somnolence to coma), mydriasis, seizures, vomiting, ECG changes (QT/QRS prolongation), ventricular tachycardia, bradycardia, hypotension, rhabdomyolysis, serotonin syndrome, and death. Published data suggest venlafaxine overdose may carry higher fatal-outcome risk than some SSRIs but lower than tricyclic antidepressants—supportive management remains standard.
Antidote
No specific antidotes for venlafaxine are known per prescribing information. Management is supportive with consideration of multiple drug involvement; activated charcoal has been used in reported cases.
Contact local poison control or medical toxicology services per facility protocol and local emergency guidance for overdose management recommendations.
Look-alike / sound-alike and error prevention
- Venlafaxine vs desvenlafaxine — related SNRIs with different dosing and products; verify generic name on every administration
- Effexor XR vs immediate-release venlafaxine — extended-release is once daily; IR products may be dosed differently; confirm formulation on MAR
- 37.5 mg vs 75 mg vs 150 mg capsules — double-check strength; taper often reduces by 75 mg weekly per labeling example
- SNRI/SSRI cross-dispense — sertraline, fluoxetine, and desvenlafaxine are not interchangeable milligram-for-milligram
- Extended-release handling — swallow capsules whole with fluid; do not divide, crush, or chew unless prescriber/pharmacy orders approved sprinkle method on applesauce
- MAOI washout — 14-day gap after MAOI before starting venlafaxine; 7 days after stopping venlafaxine before MAOI; document stop dates in MAR and reconciliation
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Food timing | Administer once daily with food at about the same time (morning or evening) per labeling. |
| Crush/split | Do not divide, crush, chew, or dissolve capsules. Labeling allows opening capsule and sprinkling contents on applesauce—swallow immediately without chewing, then drink water. |
| Onset | Antidepressant/anxiolytic benefit is not immediate; monitor early adverse effects and suicidality while waiting for therapeutic response. |
| Discharge / transfer | Flag missed doses or self-reduction—electric-shock sensations, irritability, and insomnia may appear within days of abrupt interruption. |
| Commonly missed | Home venlafaxine duplicates, new tramadol or triptan orders, and full-dose MAR when renal/hepatic impairment requires reduction. |
| Ask pharmacy when | Renal/hepatic dose unclear, dysphagia needs sprinkle technique, serotonergic stack, or discontinuation symptoms without taper orders. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Age ≥65 years | Greater hyponatremia risk; orthostatic hypotension reported; consider reduced renal clearance when dosing |
| Renal or hepatic impairment | Reduce total daily dose per labeling (renal 25–50% or ≥50%; hepatic 50% or more); individualize with pharmacy when clearance uncertain |
| Cardiovascular disease / uncontrolled hypertension | Control BP before start; SNRI may raise BP—sustained elevation can lead to adverse outcomes; dose reduction or discontinuation may be needed |
| Pregnancy | Third-trimester SNRI exposure may cause neonatal adaptation syndrome (respiratory distress, temperature instability, feeding difficulty, hypotonia, tremor, irritability) requiring prolonged hospitalization. Epidemiologic data also note possible preeclampsia and postpartum hemorrhage risks. Weigh untreated depression risks vs drug risks; pregnancy exposure registry available per labeling. |
| Lactation | Venlafaxine and ODV are present in human milk; published lactation studies estimate mean relative infant dose ~6–8% without reported infant adverse reactions in small samples. Consider clinical need, infant monitoring, and effects on milk production—not specified in the reviewed prescribing information beyond these data. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Mental status and suicidal ideation—especially first months, after dose changes, holds, or tapers
- Blood pressure at baseline and regularly during treatment; assess for sustained increases
- Sodium (hyponatremia/SIADH), especially older adults on diuretics; fall risk with dizziness; bleeding on anticoagulants
Document
- Dose, formulation (XR/IR), route, time, capsule strength, and whether capsule was swallowed whole or given via approved sprinkle method
- Suicide risk screening, discontinuation symptom assessment, serotonin syndrome assessment, and patient teaching provided
- BP trends, sodium results, taper plans, missed-dose notifications, and prescriber/pharmacy clarifications
Patient teaching
- Take exactly as prescribed at the same time daily with food; swallow the capsule whole—do not crush or chew unless pharmacy taught the sprinkle method
- Do not stop abruptly or skip multiple doses—contact the clinician before stopping; tapering may take weeks to months
- Report electric-shock sensations, severe dizziness, irritability, aggression, suicidal thoughts, fever, muscle rigidity, or confusion immediately
- Avoid starting MAOIs, St. John’s wort, or extra pain medicines without medical advice—serotonin syndrome risk
- Full benefit may take several weeks; report unusual bleeding or bruising, especially if taking blood thinners
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Patient on MAOI, linezolid, or IV methylene blue, or within required MAOI washout window (14 days after MAOI before start; 7 days after stop before MAOI)
- Multiple consecutive doses missed without prescriber restart/taper plan—high discontinuation syndrome risk
- Suspected serotonin syndrome, seizure, severe hyponatremia, or angioedema/anaphylaxis
- Patient cannot swallow capsule whole and no pharmacy-approved alternate administration is available
- Ordered dose exceeds renal/hepatic limits without documented prescriber exception; sustained hypertensive emergency pending treatment
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Venlafaxine safety on shift centers on taper discipline, serotonergic interaction surveillance, and blood pressure monitoring—especially after missed doses, new analgesic orders, or discharge planning.
1. Check-before-you-give protocol
- Right patient, drug (venlafaxine—not desvenlafaxine), formulation (XR vs IR), dose, route, and time
- Review MAR + home meds for MAOIs, linezolid, serotonergic analgesics, and duplicate SNRIs—use medication reconciliation at admission and after new orders
- Trend blood pressure and review renal/hepatic labs when dose adjustments are indicated
- Brief mood/suicide screen; assess for discontinuation symptoms if doses were missed
2. High-alert and safety badge
Not an ISMP high-alert medication — taper and serotonin checks are mandatoryAlthough not classified in the same tier as IV anticoagulants or concentrated electrolytes, venlafaxine carries a boxed warning for suicidality and labeling emphasizes serious discontinuation syndrome with postmarketing reports of suicide and aggression during dose reduction—treat taper and interaction checks as mandatory high-risk nursing steps.
3. Clinical workflow: hold and question rules
- Hold and clarify after two or more missed XR doses until prescriber/pharmacy defines restart or taper plan
- Stop and notify prescriber if serotonin syndrome criteria met—do not administer next dose
- Coordinate gradual taper with prescriber when discontinuing after prolonged therapy—never remove from MAR without a taper order
4. Critical teach-back questions
- “What happens if you miss several doses or stop suddenly?” — patient knows not to stop abruptly, will call clinician for electric-shock sensations, dizziness, irritability, or suicidal thoughts, and understands taper may take weeks
- “What should you do before taking a new pain medicine or antibiotic?” — contact prescriber/pharmacy first because some drugs interact (serotonin syndrome or bleeding risk)
5. Care coordination
Pharmacist: Formulation verification (XR vs IR), renal/hepatic dose checks, serotonergic interaction review, and taper planning after missed doses
Prescriber / mental health: Suicide risk management, gradual discontinuation orders, MAOI washout timing, and BP management when SNRI raises pressure
🧠 Quick mental checklist
- Is this venlafaxine—not desvenlafaxine—and the correct XR/IR product and strength?
- Were any doses missed this week without a prescriber taper/restart plan?
- Any new tramadol, triptan, SSRI, or MAOI on the MAR or home med list?
- Is blood pressure controlled and trending since therapy started or dose changed?
- If agitation, clonus, or electric-shock sensations appear, is this serotonin syndrome or discontinuation syndrome?
Venlafaxine NCLEX practice questions
Practice NCLEX-style clinical judgment practice for venlafaxine using a tabbed case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, trend interpretation, matrix urgency sorting, clinical judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes around SNRI tapering, blood pressure, and serotonin safety.
Select a tab to view MAR, labs, Vitals, and nursing note details for this case.
- Venlafaxine XR 150 mg PO daily — last given 3 days ago (patient left unit for procedure; doses not administered)
- Tramadol 50 mg PO q6h PRN pain — new order; 1 dose at 0730 today
- Buspirone 10 mg PO BID — continued
- Lisinopril 10 mg PO daily — 0800 given
- Na 134 mmol/L (prior 138)
- Serum creatinine 1.6 mg/dL; eGFR ~42 mL/min (moderate renal impairment)
- Not specified in the reviewed prescribing information for routine venlafaxine level monitoring
- BP 158/96 mmHg (baseline on admission 128/78), HR 104/min, RR 18, SpO2 98% room air, temp 37.0 °C
- Orthostatics: reports lightheadedness standing; BP 152/94 lying → 146/88 standing
- 52-year-old with MDD on medical unit; reports “brain zaps,” irritability, and insomnia since missing venlafaxine
- 0900: Hyperreflexia noted at ankles; patient anxious but oriented
- 0915: Son asks why nurse wants to give “Effexor” when home bottle says venlafaxine—verify same drug
- 0920: Nurse reviewing tabs before scheduled 150 mg dose
Answer key & rationale
Frequently asked questions
Why is missing venlafaxine doses a nursing safety priority?
Abrupt discontinuation or dose reduction can cause discontinuation syndrome with sensory disturbances (including electric-shock sensations), agitation, insomnia, dizziness, and suicidal thoughts. Postmarketing reports include completed suicide and severe aggression during dose reduction. Hold and clarify with prescriber/pharmacist after consecutive missed doses rather than silently restarting the full dose.
When should a nurse hold venlafaxine and contact the prescriber or pharmacist?
Hold when MAOIs, linezolid, or intravenous methylene blue are present or within required washout windows, when serotonin syndrome is suspected, when sustained blood pressure elevation requires treatment, when severe hyponatremia symptoms appear, when the patient cannot swallow the capsule using an approved method, or when discontinuation symptoms emerge without a taper plan.
Is there a specific antidote for venlafaxine overdose?
No specific antidotes for venlafaxine are known per prescribing information. Overdose management is supportive with consideration of multiple drug involvement. Contact local poison control or medical toxicology services per facility protocol and local emergency guidance.
Can venlafaxine XR capsules be crushed for administration?
Do not divide, crush, chew, or dissolve extended-release capsules. Labeling allows opening the capsule and sprinkling the entire contents on a spoonful of applesauce, swallowed immediately without chewing, followed by water. Otherwise contact pharmacy for an alternate plan.
Why is venlafaxine confused with desvenlafaxine on nursing units?
Desvenlafaxine is the major active metabolite of venlafaxine and the names sound similar, but they are distinct products with different dosing. Always verify the exact generic name, brand (Effexor XR), formulation (XR vs IR), and capsule strength before administration.
References
-
U.S. National Library of Medicine. EFFEXOR XR (venlafaxine hydrochloride) extended-release capsules — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53c3e7ac-1852-4d70-d2b6-4fca819acf26
-
U.S. Food and Drug Administration. FDA drug safety communication: Suicidal thoughts and behavior in antidepressant drugs.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-suicidal-thoughts-and-behavior-antidepressant-drugs
-
Drugs and Lactation Database (LactMed). Venlafaxine. Bethesda (MD): NICHD.https://www.ncbi.nlm.nih.gov/books/NBK547739/
-
Massachusetts General Hospital Center for Women’s Mental Health. National Pregnancy Registry for Antidepressants.https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants
-
U.S. National Library of Medicine. EFFEXOR XR — Medication Guide. DailyMed.https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=53c3e7ac-1852-4d70-d2b6-4fca819acf26
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.